ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024

ENDRA Life Sciences Inc.

Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.
Amendment to Certificate of Incorporation filed with Delaware Secretary of State on Nov 4, 2024, effective 12:01 a.m. ET on Nov 7, 2024.
Common stock will trade on split-adjusted basis under new CUSIP 29273B 500 beginning Nov 7, 2024.
Each issued share of common stock will be reclassified and converted into 1/35 of a share.
No change to the par value of $0.0001 per share or the authorized number of shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.